Table 1.
Clinical characteristics of patients with IgA nephropathy.
| Characteristics | Total Cohort | Tertiles of plasma D-dimer (µg/L FEU) |
P | ||
|---|---|---|---|---|---|
| 1st tertile ≤170 |
2nd tertile 171-337 |
3rd tertile ≥338 |
|||
| N | 1818 | 689 | 565 | 564 | |
| Male, n % | 956 (52.59) | 277(40.20) | 330(58.41) | 349(61.88) | <0.001 |
| Age, yr, mean ± s.d. | 38.61 ± 12.20 | 36.77 ± 11.14 | 38.51 ± 11.78 | 40.96 ± 13.45 | <0.001 |
| MAP, mmHg, mean ± s.d. | 95.02 ± 14.02 | 95.19 ± 13.77 | 95.30 ± 14.38 | 94.56 ± 13.95 | 0.624 |
| Proteinuria, g/d, median, IQR | 0.94 (0.49 to 1.82) | 0.76(0.41 to 1.40) | 0.89(0.49 to 1.54) | 1.35(0.67 to 2.79) | <0.001 |
| eGFR, mL/min/1.73 m2, mean ± s.d. | 83.87 ± 29.24 | 86.45 ± 28.06 | 84.98 ± 27.35 | 78.22 ± 31.05 | <0.001 |
| Serum albumin, g/L | 38.99 ± 6.17 | 40.67 ± 5.61 | 39.55 ± 5.00 | 36.39 ± 6.99 | <0.001 |
| Plasma D-dimer µg/L FEU, median, IQR | 220 (170 to388.5) | 170.00 (111.00 to 170.00) | 236.00(204.00to 282.00) | 567.50(411.00to 897.00) | <0.001 |
| Plasma APTT, s | 27.69 ± 4.24 | 27.82 ± 3.86 | 27.57 ± 3.95 | 27.67 ± 4.88 | 0.683 |
| Plasma PT, s | 11.17 ± 0.95 | 11.17 ± 0.92 | 11.15 ± 0.79 | 11.19 ± 1.12 | 0.785 |
| CKD stages, n (%) | |||||
| 1 | 839 (46.15) | 343(49.78) | 273(48.32) | 223(39.54) | 0.001 |
| 2 | 540(29.70) | 209(30.33) | 176(31.15) | 155(27.48) | 0.362 |
| 3 | 383(21.07) | 123(17.85) | 101(17.88) | 159(28.19) | <0.001 |
| 4 | 56(3.08) | 14(2.03) | 15(2.65) | 27(4.79) | 0.015 |
| Oxford classification, n (%) | |||||
| M1 | 251(13.81) | 122(17.71) | 74(13.10) | 55 (9.75) | <0.001 |
| E1 | 122(6.71) | 45(6.53) | 28(4.96) | 49(8.69) | 0.042 |
| S1 | 1205(66.28) | 442(64.15) | 399(70.62) | 364(64.54) | 0.031 |
| T1-T2 | 189(10.40) | 44(6.39) | 64(11.33) | 81(14.36) | <0.001 |
| C1-C2 | 849(46.70) | 287(41.65) | 266(47.08) | 296(52.48) | 0.001 |
| Follow-up and Outcome | |||||
| Follow-up duration, mo, median, IQR | 25.67 (13.03-47.44) | 27.32(13.48-48.88) | 23.23(12.58-41.18) | 24.40(12.43-42.90) | 0.003 |
| 50% eGFR decline, % | 114 (6.27) | 42(6.10) | 27(4.78) | 45(7.98) | 0.083 |
| Kidney failure, % | 92 (5.06) | 32(4.64) | 19(3.36) | 41(7.27) | 0.009 |
| Composite outcome, % | 126 (6.93) | 47(6.82) | 28(4.96) | 51(9.04) | 0.026 |
Note: Values for continuous variables are expressed as mean ± standard deviation or median [interquartile ranges]; counts (percentages) are used for categorical variables. Composite outcome was defined as a 50% decrease in eGFR or kidney failure. M, mesangial hypercellularity; E1, endocapillary hypercellularity; S, segmental glomerulosclerosis/adhesion; T, severity of tubular atrophy/interstitial fibrosis; C, presence of crescent; APTT, activated partial thromboplastin time; PT, prothrombin time.